Tenecteplase (TNK) in the Treatment of Intracerebral Hemorrhage (ICH)

Inclusion Criteria * Patient/legally authorized representative has signed the Informed Consent Form. * Ability to comply with the study protocol, in the investigator's judgment. * Patients 18 to 80 years of age with an ICH had occurred within 24 hours before admission. * Spontaneous supratentorial (basal ganglia, thalamus, lobar) ICH ≥30 mL measured utilizing the ABC/2 method. * Subjects with a GCS score of 5-14. * NIHSS ≥6. * Stability CT scan done at least 6 hours after baseline CT showing clot stability (growth \<5 mL as measured by ABC/2 method). If the hematoma volume measured on the stability CT scan increases by 5 mL or more, a second stability CT scan will be performed 12 hours later. * Sustained systolic blood pressure (SBP) \<180 mm Hg for six hours recorded closest to the time of drug administration. * Symptoms must be present less than 24 hours prior to baseline CT scan. * Baseline Rankin score of 0 or 1. Exclusion Criteria * Presence of infratentorial parenchymal bleeding. * Presence of a hemorrhage extending to the midbrain. * An unknown time of onset or the symptoms onset more than 24 hours prior to admission. * Pregnancy. * Inability to obtain written informed consent from subject or legal representative. * Sustained SBP \>180 mm Hg for six hours recorded closest to the time of drug administration. * Age \<18 and \>80 years. * Radiological evidence of arterio-venous malformation, aneurysm, amyloid angiopathy, Moyamoya disease, hemorrhagic conversion of an i…